ReviewUrologic oncology2021
A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.
Review in Urologic oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Discovery of NKT2152, a Potent and Selective HIF-2α Inhibitor with Favorable Pharmacokinetic Properties.ACS medicinal chemistry letters · 2026Article
- International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinoma.Frontiers in oncology · 2026Article
- Association of Histologic Growth Patterns and Some Histopathologic Features in Clear Cell Renal Cell Carcinoma with Patient's Survival after Nephrectomy: A Cross-Sectional Study.Iranian journal of pathology · 2025Article
- Article
- Adjuvant therapy in renal cell carcinoma (RCC): progress, at last.Translational cancer research · 2024Review
- Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy.BMC cancer · 2023Article
- Preclinical optimization of a diode laser-based clamp-free partial nephrectomy in a large animal model.Scientific reports · 2023Article
- Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma.The oncologist · 2023Article
- Determining Front-Line Therapeutic Strategy for Metastatic Clear Cell Renal Cell Carcinoma.Cancers · 2022Review
- New Paradigms for Cytoreductive Nephrectomy.Cancers · 2022Review
- Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib withCell cycle (Georgetown, Tex.) · 2022Article
- Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature.Journal of kidney cancer and VHL · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The diagnosis, evaluation and management of patients with renal cell carcinoma has transformed in the 21st century. Utilizing biological discoveries and technological advances, the field has moved from blunt surgical and largely ineffective medical treatments, to nuanced and fine-tuned approaches based on biology, extent of disease and patient preferences. In this review we will summarize the last 25 years of progress in kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.